Efficacy and safety of 10‐deazaaminopterin in the treatment of rheumatoid arthritis: A one‐year continuation, double‐blind study

Publisher Website
Google Scholar
Abstract
Objective. To determine the long‐term safety and efficacy of 10‐deazaaminopterin (10‐DAM) in the treatment of rheumatoid arthritis (RA). Methods. A 1‐year continuation of an initial 15‐week randomized, double‐blind clinical trial of 10‐DAM and methotrexate (MTX). Results. 10‐DAM (n = 10) and MTX (n = 8) had comparable safety and efficacy profiles. One 10‐DAM—treated and 2 MTX‐treated patients experienced transient side effects; 1 MTX‐treated patient experienced recurrent nausea and discontinued MTX. Conclusion. 10‐DAM appears to be as beneficial and as safe as MTX for the treatment of RA.